Prospective Validation of Objective Prognostic Score for Advanced Cancer Inpatients in South Korea: A Multicenter Study
- Author(s)
- Yoon Seok Joon; Suh Sang-Yeon; Lee Yong Joo; Park Jeanno; Hwang Sunwook; Lee Sanghee Shiny; Ahn Hong Yup; Koh Su-Jin; Park Keon Uk
- Keimyung Author(s)
- Park, Keon Uk
- Department
- Dept. of Internal Medicine (내과학)
- Journal Title
- Journal of Palliative Medicine
- Issued Date
- 2017
- Volume
- 20
- Issue
- 1
- Keyword
- cancer; palliative care; prognostic score; survival; validation
- Abstract
- Background: Objective Prognostic Score (OPS) was developed as an easy and simple prognosticating tool in South Korea. It has been validated retrospectively in a single center in South Korea.
Objective: We aimed to validate the OPS prospectively for advanced cancer inpatients in South Korea using a multicenter study.
Design: This was a prospective cohort study.
Setting/Subjects: We enrolled 243 advanced cancer patients admitted in five palliative care units in South Korea from May 2013 till March 2015. Seven members of the Korean Palliative Medicine Research Network who are experts of palliative care led the study.
Measurements: Clinical variables (dyspnea/anorexia/performance status) and laboratory variables (total leukocyte counts/serum total bilirubin/serum creatinine/lactate dehydrogenase) were collected at the enrollment. Survival time was calculated as days from enrollment to death during admission.
Results: A total of 217 patients were included in the final analysis (feasibility: 89.3%). Survival time of the higher OPS group (OPS ≥3) and the lower OPS group (OPS <3) was 10.0 (95% confidence interval (CI) 7.72–12.28) days and 32.0 (95% CI 25.44–38.56) days, respectively. There were significant differences between the 2 groups (p < 0.001). Overall accuracy of OPS ≥3 for predicting survival less than three weeks was 71.0%.
Conclusions: OPS was successfully validated using a prospective multicenter study in South Korea. It is a useful method to predict three-week survival of Korean inpatients with advanced cancer.
- 공개 및 라이선스
-
- 파일 목록
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.